Caribou Biosciences, Inc. 8-K

What Happened
Caribou Biosciences, Inc. (CRBU) filed an 8-K reporting the results of its June 17, 2026 annual meeting of stockholders. Three Class II director nominees were elected to serve until the 2029 annual meeting. Stockholders also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. A proposed amendment to the company’s certificate of incorporation to add broader officer exculpation under Delaware law was not approved. Although stockholders approved a possible adjournment to solicit additional votes on that amendment, the company elected not to adjourn.

Key Details

• Directors elected (terms to 2029):
  • Andrew Guggenhime, M.B.A.: 31,554,511 For; 9,585,265 Withheld; 27,098,425 Broker Non-Votes.
  • David Johnson, M.B.A.: 31,725,652 For; 9,414,124 Withheld; 27,098,425 Broker Non-Votes.
  • Nancy Whiting, Pharm.D.: 31,694,175 For; 9,445,601 Withheld; 27,098,425 Broker Non-Votes.
• Auditor ratified: Deloitte & Touche LLP approved by vote of 67,457,482 For; 337,911 Against; 442,808 Abstain; 0 Broker Non-Votes.
• Charter amendment failed: Proposal to add officer exculpation was not approved — 37,483,637 For; 3,513,785 Against; 142,354 Abstain; 27,098,425 Broker Non-Votes.
• Adjournment vote: Stockholders approved a possible adjournment (37,615,389 For), but the company chose not to adjourn the meeting.

Why It Matters

• Board continuity: The re-election of the three Class II directors preserves the current board composition through 2029, which matters for strategic oversight and leadership continuity.
• Audit continuity: Ratification of Deloitte & Touche LLP keeps the company’s external audit relationship unchanged for 2026, reducing near-term audit-related uncertainty.
• Governance note: Shareholders rejected a proposed increase in officer exculpation from the company’s certificate of incorporation. That vote reflects shareholder sentiment on limiting officer liability and is a governance item investors may watch for its potential to influence management accountability and future proxy proposals.